Is there a type of sleep apnea in which breathing ceases due to absent respiratory drive rather than upper‑airway obstruction?

Yes, Central Sleep Apnea (CSA) is a distinct type where breathing stops due to absent respiratory drive, not airway obstruction.

Central sleep apnea is fundamentally different from obstructive sleep apnea—in CSA, the brain temporarily fails to send signals to breathe, resulting in cessation of both airflow and respiratory effort, whereas obstructive sleep apnea involves continued breathing effort against a blocked airway 1.

Key Distinguishing Features

Mechanism of breathing cessation:

• CSA: Transient cessation of ventilatory motor output from the brainstem—the respiratory drive simply stops 1
• OSA: Upper airway physically collapses or obstructs while the brain continues sending signals to breathe

During sleep, particularly non-REM sleep, the normal "wakefulness drive to breathe" is removed, making respiration critically dependent on carbon dioxide levels (PaCO2). In CSA, when inhibitory influences predominate over excitatory ones, the brain's respiratory control center becomes unstable and stops sending breathing signals 1.

Clinical Categories of CSA

The International Classification of Sleep Disorders recognizes 6 distinct categories of central sleep apnea 1:

1. Primary CSA (idiopathic)
2. CSA with Cheyne-Stokes respiration (frequently due to heart failure)
3. CSA due to medication or substance (especially opioids)
4. CSA due to a medical disorder (without Cheyne-Stokes pattern)
5. Treatment-emergent CSA (develops during OSA treatment with CPAP)
6. CSA due to high altitude

Pathophysiology Varies by Cause

The mechanism differs depending on the underlying condition 1:

• Most CSA types: Post-hyperventilation phenomenon where excessive breathing lowers CO2 below the apneic threshold, triggering breathing cessation
• Opioid-induced CSA: Unique pathway with depressed central respiratory drive and decreased chemosensitivity (unlike other CSA types that have increased chemosensitivity) 1
• Heart failure-related CSA: Prolonged circulation time and increased CO2 sensitivity contribute to breathing instability 2

Diagnostic Distinction

Polysomnography (PSG) is essential to differentiate CSA from OSA. The key diagnostic feature is that >50% of respiratory events must be central in nature (showing absence of respiratory effort coupled with absent airflow) 1.

Common pitfall: In patients with predominantly hypopneas rather than clear apneas, distinguishing central from obstructive events can be challenging without esophageal pressure monitoring 1. Many patients also present with mixed disorders where both central and obstructive events occur 1.

Clinical Significance

CSA carries serious prognostic implications 1:

• Associated with increased mortality and hospitalization, particularly in heart failure patients
• Nearly one-fifth of CSA patients died within 5 years of diagnosis in a 21-year Veterans Health Administration study
• Causes sleep fragmentation, daytime sleepiness, insomnia, and poor quality of life

Treatment Differs Fundamentally from OSA

Because the mechanism is absent respiratory drive rather than obstruction, treatment approaches differ 1:

• Acetazolamide (respiratory stimulant) is suggested for various CSA etiologies
• Transvenous phrenic nerve stimulation may be considered for primary CSA and heart failure-related CSA
• Standard CPAP may work for some cases but is often insufficient
• Adaptive servo-ventilation (ASV) can be effective but is contraindicated in heart failure patients with ejection fraction ≤45% due to increased mortality risk 3

The fundamental distinction is that CSA represents a failure of the brain's respiratory control system, not a mechanical airway problem, requiring entirely different diagnostic and therapeutic approaches.